ImmunAbs Inc., founded in 2017, is a promising player in the Biotechnology sector, focused on addressing autoimmune diseases via specialized antibody therapeutics. The company is led by a team with extensive experience, positioning itself as a significant contributor to the Health Care and Health and Wellness industries.
In April 2024, ImmunAbs Inc. successfully completed a Phase 1 clinical trial in the United States and is now gearing up for a Phase 2 trial. Their recent success underscores their potential to become a global leader in biopharmaceutical development. Their slogan, "Hope for patients, dreams for all," encapsulates their patient-centric vision.
Having secured a Series B investment on 31 October 2021 with backing from Nice Investment Partners, the company is on a strategic path poised for accelerated growth and innovation in its next phase of clinical evaluations.
